You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
华检医疗(01931.HK)首日挂牌低开8.47%最新市值37亿港元
格隆汇 07-12 09:24

格隆汇7月12日丨IPO那点事(ID:ipopress)消息,华检医疗(01931.HK)首日挂牌低开8.47%,截至9时20分,跌8.%,报价2.81港元,成交额 1548.77万港元 ,最新市值37.469亿港元。

华检医疗(01931.HK)于2019年2月28日递交上市申请,并于6月28日通过上市聆讯。公告显示,华检医疗全球发售3.334亿股,其中香港发售约3334万股,国际发售约3亿股;发售价每股3.07港元;每手1,000股;预期2019年7月12日上市。

公开发售适度超额认购,相等于根据香港公开发售初步可供认购的香港发售股份总数33,340,000股的约2.212倍。

华检医疗是中国IVD产品分销商。于2017年,原集团是上海IVD市场第三大分销商,威士达为中国第四大一级IVD分销商。公司也有自由品牌IVD产品的研发、开发、生产及销售。

中国第四大一级IVD分销商威士达为其全资子公司,自1997年以来,其一直为希森美康凝血产品在中国的独家分销商,拥有独家分销权,向中国分销凝血分析仪、试剂及其他耗材。

中国IVD市场可分为六个主要类别:血液学及体液、临床化学、免疫、分子、微生物学及实时检验。免疫、临床化学以及血液学及体液分析为前三大分类,临床应用最为广泛。根据弗若斯特沙利文报告,中国IVD市场的免疫、临床化学以及血液学及体液测试的合计市场份额约为65.4%。

根据弗若斯特沙利文报告,中国IVD市场由2014年的约人民币293亿元增至2018年的约人民币713亿元。因中国人口老龄化趋势加剧、人均医疗支出增长及技术进步,预计中国IVD市场将于2023年达到约人民币1,730亿元,2018年至2023年的复合年增长率约为19.4%。IVD占中国医疗器械整体市场的份额估计将由2018年约13.5%增至2023年的约16.3%。

公司业务由分销业务和自有品牌产品业务两个业务分部组成。于2016年度、2017年度及2018年1-9月,作为原集团业务基石的的分销业务分部实现收益分别为2.83亿元人民币、3.19亿元及2.75亿元,分占原集团总收益的97.5%、94.4%及98.5%。

IPO那点事获悉,于2016年、2017年及2018年度,该公司实现收益分别为人民币2.90亿元、3.38亿元及4.14亿元;毛利分别为8389.8万元、1.08亿元及1.17亿元;年内溢利分别为5716.6万元、1.13亿元及9950.8万元。

公告称,所得款项净额约为9.32亿港元。其中,约49.6%用于结清收购威士达60%股权的现金代价的未偿还结余;约32.9%,用于根据收购事项向公司及威士达现有股东派付部分股息;约6.8%用于在分销业务项下扩大客户群;约3.5%用于继续研发自有品牌产品;约2.6%用于扩展分销业务并提升分销价值链;约4.6%用于营运资金及一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account